单次囊胚活检可同时检测遗传病与非整倍体:一种成功的临床方法
该连续病例系列研究分析2011年10月至2016年5月304个胚胎植入前遗传学诊断(PGD)周期中的1122个囊胚,在同一活检样本中同时进行PGD和胚胎植入前遗传学筛查(PGS)。结果显示,50.6%经PGD诊断为无遗传病或平衡的囊胚为非整倍体;仅PGD时28.6%周期无可用囊胚,加做PGS后升至39.8%(Mc Nemar检验P < 0.001)。
要点
- 经PGD诊断为无遗传病或平衡的囊胚中,50.6%为非整倍体,避免了潜在失败移植。
- 仅PGD无可用囊胚周期为28.6%,加做PGS后升至39.8%(Mc Nemar检验P < 0.001)。
- 202次移植的临床妊娠率49.0%、种植率47.7%、流产率9.9%,已分娩66次70名健康婴儿。
核心结论
- 在囊胚活检样本中同时检测非整倍体和遗传病或染色体异常,可避免移植植入潜力低的胚胎,获得良好临床结局。
研究设计与样本
- 该连续病例系列研究于2011年10月至2016年5月实施,分析304个PGD周期(单基因病163个、染色体结构异常141个)获得的1122个囊胚。
- 平均女性年龄35.4 ± 4.2岁,所有活检均在囊胚阶段进行,采用全基因组扩增(WGA)后行PCR检测单基因病、行array-CGH检测所有周期。
主要发现
- 2809个成熟卵母细胞(2718个新鲜、91个冻融)注射后受精率75.5%(N = 2120),形成2102个胚胎;另24个未行遗传检测的冷冻胚胎成功复苏用于遗传筛查。
- 2126个胚胎培养的囊胚形成率为52.8%(N = 1122),所有囊胚在培养第4天至第7天活检。
- 遗传分析后309个(27.5%)囊胚可移植,42个为二倍体/非整倍体嵌合,55个无结果,716个因遗传病或染色体结构异常和/或倍性状态不可移植。
- 316个(占PGD后可移植囊胚的50.6%、占活检囊胚总数的28.2%)经PGD诊断为遗传病或染色体结构异常健康的囊胚为非整倍体。
- 304个PGD/PGS周期中,仅PGD分析后28.6%(N = 87)无可用囊胚,加做PGS后升至39.8%(N = 121)(Mc Nemar检验P < 0.001)。
关键数值与推荐
- 经PGD诊断为无遗传病或平衡的囊胚中,50.6%为非整倍体(占活检囊胚总数28.2%)。
- 仅PGD时无可用囊胚周期比例为28.6%(N = 87),加做PGS后为39.8%(N = 121),差异Mc Nemar检验P < 0.001。
- 202次移植的临床妊娠率49.0%、种植率47.7%、流产率9.9%。
临床怎么用
- 作者认为,当为预防遗传病传播而必须进行活检时,应同时分析囊胚的遗传状态,以避免该类患者中无用的胚胎移植。
- 作者指出,本研究中316个非整倍体健康囊胚若未行PGS而被移植,可能导致植入失败、流产或分娩受累于不同综合征的活婴。
局限性
- 由于进行双重遗传分析,周期取消率可能高于预期。
- 因此,应特别谨慎地起草和解释知情同意,以避免患者退出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can simultaneous detection of aneuploidies and genetic diseases or chromosomal aberrations in blastocysts reduce the chance of transferring embryos with low implantation potential, guaranteeing good clinical outcomes? SUMMARY ANSWER: The screening for chromosomal aneuploidies revealed that 50.6% of blastocysts diagnosed free of genetic disease or balanced, were aneuploid, therefore avoiding the transfer of blastocysts potentially resulting in implantation failures, miscarriages, or in some cases, in health affected live births. WHAT IS KNOWN ALREADY: PGD is applied in patients at risk of transmitting genetically inheritable diseases to their offspring. It has been demonstrated that aneuploidies can involve chromosomes other than those investigated with PGD, affecting embryo implantation competence. Performing the biopsy at blastocyst level produces higher clinical outcomes allowing a more accurate diagnosis, compared to blastomere biopsy. STUDY DESIGN, SIZE, DURATION: This consecutive case series study was performed from October 2011 to May 2016. Clinical and biological outcomes from 1122 blastocysts obtained in 304 PGD cycles for monogenic diseases (N = 163) or chromosomal rearrangements (N = 141) were analyzed. When the blastocyst resulted transferable after the PGD analysis or chromosomal rearrangement analysis, its ploidy status by mean of preimplantation genetic screening (PGS) was also detected using the same biopsy sample. Mean female age was 35.4 ± 4.2 years old. All biopsies were performed at blastocyst stage and analyzed by Whole Genome Amplification (WGA) followed by PCR for monogenic diseases, and by array-comparative genotype hybridization (array-CGH) for all cycles. PARTICIPANTS/MATERIALS, SETTING, METHOD: All mature oocytes retrieved were injected and cultured individually until the blastocyst stage at 37°C, 6% CO2, 5% O2. When the blastocyst was formed, it was biopsied and vitrified, awaiting the genetic results. The frozen-thawed embryo transfer was performed in a subsequent cycle. In some cases, when the blastocyst was obtained within the morning of Day 5 of culture, it had been maintained in culture and transferred on Day 6, after receiving the genetic report. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 2809 (2718 fresh and 91 frozen-thawed) mature oocytes were injected with a fertilization rate of 75.5% (N = 2120), leading to the development of 2102 embryos. A further 24 frozen embryos, previously vitrified without any genetic testing, were successfully warmed for genetic screening. A total of 2126 embryos were cultured with a blastocyst formation rate of 52.8% (N = 1122); all of them were biopsied from Day 4 to Day 7 of culture. After the genetic analysis, 309 (27.5%) blastocysts resulted transferable, both for monogenic disease or translocation and for their ploidy status, 42 were diploid/aneuploid mosaic, 55 were no result and 716 were not transferable, due to genetic disease or chromosomal rearrangement and/or for their ploidy status. Of note, 316 (50.6% of transferable blastocysts after PGD and 28.2% of total number of biopsied blastocysts) of the blastocysts resulted healthy for the genetic disease or chromosomal rearrangement were aneuploid. Out of 304 PGD/PGS cycles performed, 28.6% (N = 87) resulted in no-transferable blastocysts after only PGD analysis; this percentage increased to 39.8% (N = 121) when also PGS was carried out (Mc Nemar test P < 0.001). A total of 202 embryo-transfers were performed, 53 fresh and 149 cryopreserved, in which 218 healthy or carrier euploid blastocysts were transferred. Clinical pregnancy, implantation and miscarriage rates were 49.0, 47.7 and 9.9%, respectively. To date, 66 deliveries occurred with 70 healthy babies born and 13 pregnancies are still ongoing. Finally, 91 euploid healthy blastocysts are still cryopreserved waiting to be transferred. LIMITATIONS, REASONS FOR CAUTION: A higher than expected cycle cancellation rate could be found due to the double genetic analysis performed. For this reason, particular care should be taken in drafting and explaining informed consent, in order to avoid patient drop out. WIDER IMPLICATIONS OF THE FINDINGS: When the biopsy has to be performed in order to prevent the transmission of an inheritable disease, it should be mandatory to analyze also the genetic status of the blastocyst, avoiding useless embryo-transfers in this particular category of patients. In our study, 316 aneuploid healthy blastocysts could have been transferred without performing PGS, leading to implantation failures, miscarriages, or in some cases, to live births affected by different syndromes. STUDY FUNDING/COMPETING INTEREST(S): No specific funding was obtained for this study. None of the authors have any competing interests to declare. TRIAL REGISTRATION NUMBER: Not applicable.
引用
- Minasi MG, Fiorentino F, Ruberti A, et al. Genetic diseases and aneuploidies can be detected with a single blastocyst biopsy: a successful clinical approach. Hum Reprod. 2017. PMID: 28633287. doi:10.1093/humrep/dex215
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。